Phase 1 study of veliparib (ABT-888), a poly(ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

PURPOSE: Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and −2. PARP-1 expression may be increased in cancer, and this increase confers resistance to cytotoxic agents. We aimed to determine the recommended phase 2 dose (RP2D), maximum tolerated dose (MTD), dose-limiting toxic...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Chemother Pharmacol
Hoofdauteurs: Appleman, Leonard J., Beumer, Jan H., Jiang, Yixing, Lin, Yan, Ding, Fei, Puhalla, Shannon, Swartz, Leigh, Owonikoko, Taofeek K., Harvey, R. Donald, Stoller, Ronald, Petro, Daniel P., Tawbi, Hussein A., Argiris, Athanassios, Strychor, Sandra, Pouquet, Marie, Kiesel, Brian, Chen, Alice P., Gandara, David, Belani, Chandra P., Chu, Edward, Ramalingam, Suresh S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7825275/
https://ncbi.nlm.nih.gov/pubmed/31549216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03960-w
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items